resiquimod has been researched along with Respiratory Syncytial Virus Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Curtin, JA; Custovic, A; Edwards, MR; Fontanella, S; Haider, S; Howard, R; Johnston, SL; Lin, L; Rattray, M; Regis, E; Simpson, A | 1 |
| Johansson, C; Makris, S | 1 |
| Chen, M; Graham, BS; Johnson, TR; Rao, S; Seder, RA | 1 |
3 other study(ies) available for resiquimod and Respiratory Syncytial Virus Infections
| Article | Year |
|---|---|
Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study.
Topics: Adolescent; Birth Cohort; Cohort Studies; Female; Humans; Imidazoles; Immunity, Innate; Interferons; Leukocytes, Mononuclear; Male; Oligodeoxyribonucleotides; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Respiratory Tract Infections; Rhinovirus; SARS-CoV-2; Sex Factors | 2021 |
R848 or influenza virus can induce potent innate immune responses in the lungs of neonatal mice.
Topics: Adaptor Proteins, Vesicular Transport; Age Factors; Animals; Animals, Newborn; Cyclic AMP; Cytokines; Disease Models, Animal; Host-Pathogen Interactions; Imidazoles; Immunity, Innate; Lung; Macrophages, Alveolar; Mice; Myeloid Differentiation Factor 88; Orthomyxoviridae; Orthomyxoviridae Infections; Respiratory Syncytial Virus Infections; Signal Transduction | 2021 |
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Topics: Adjuvants, Immunologic; Animals; Antibody Formation; Cell Line; Glycine; Humans; Imidazoles; Immunity, Cellular; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Viruses; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Virulence | 2009 |